Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
What Drives Catalyst Pharmaceuticals Above 250% This Year?
by Zacks Equity Research
We take a look at the factors that drive phenomenal growth in Catalyst Pharmaceuticals' (CPRX) share price in 2017.
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse
by Zacks Equity Research
Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.
Catalyst Initiates Phase II Study for Pipeline Drug Firdapse
by Zacks Equity Research
Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.
Catalyst (CPRX) Focused on Development of Pipeline Candidates
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.
Catalyst (CPRX) Posts Narrower than Expected Loss in Q2
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.
Catalyst (CPRX) Shows Strength: Stock Adds 9.6% in Session
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) shares rose around 10% in the last trading session.
Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?
by Zacks Equity Research
Shares of Catalyst Pharmaceuticals, Inc. (CPRX) have soared 161% this year so far, massively outperforming the Zacks classified Medical Drugs industry's gain of 10.2%.
Why Is Catalyst Pharmaceuticals (CPRX) Up 25.5% Since the Last Earnings Report?
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals (CPRX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Catalyst Pharmaceuticals Inc (CPRX).
Catalyst Pharmaceuticals Focuses on Development of Firdapse
by Zacks Equity Research
We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.
Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.
Catalyst (CPRX) Up 16.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares rose over 18% on the day.
Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
by Zacks Equity Research
We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.
Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.